Mizuho Maintains Outperform on Cytokinetics, Raises Price Target to $100

Mizuho analyst Salim Syed has maintained an 'Outperform' rating on Cytokinetics (NASDAQ: CYTK) and increased the price target from $84 to $100. This adjustment reflects a positive outlook on the company's performance.